Nia Health, a start-up supported by EIT Health and a spin-off of Charité Universitätsmedizin Berlin, has received EUR 3.5 million in seed funding. The funding was obtained from High-Tech Gründerfonds, adesso ventures, Ventura BioMed Investors, and Dr. Kurt Schwarz, a pharmaceutical industry expert, along with other investors.
The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. With its platform, Nia Health addresses an often highly underserved patient population and generates treatment-relevant real-world evidence.
Nia Health’s founders plan to use the seed round funding to expand. They are aiming to grow the market share in German-speaking countries, launch in other EU countries in the next 24 months, and prepare for US market entry. They will also use the funding to develop innovative, AI-based technology that integrates machine vision, natural language processing and teledermatology.
The seed funding allows us to expand our AI and development capabilities to massively best address the individual needs of patients with chronic skin conditions. In addition, we benefit from the cross-sector expertise of our strong consortium of investors. With Ventura BioMed Investors, we have a partner with many years of experience in the pharmaceutical industry on board, while in parallel, we can draw on adesso’s expertise to scale our IT landscape.
Oliver Welter, co-founder and CTO of Nia Health
Through EIT Health programmes, Nia Health has received valuable access to a network of relevant industry partners, European investors, and funding.
Through EIT Health, we have received great support and trust in the digital health scene.
Tobias Seidl, CEO of Nia Health
Is your start-up looking for help to grow?